Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

The Avalanche Approach

Currently, wet age-related macular degeneration is treated with frequent injections of anti-VEGF protein directly into the eyeball. This creates a burden for both patients and physicians, and limits access for those who are not able to comply with frequent visits and injections.

Learn More About The Avalanche Approach:

Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO

MENLO PARK, Calif., Nov. 20, 2015 -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today announced the appointment of Paul B. Cleveland to chief executive officer (CEO) and to the Board of Directors effective December 9. He also will serve as principal financial officer of Avalanche on an interim basis. Mr. Cleveland, previously the chief executive officer of Celladon Corporation, brings more than 20 years of leadership experience to Avalanche, including management and operational experience across the biotechnology industry. This includes positions at multiple public biotechnology companies, including CEO, president, chief financial officer and Board member as well as chief operating officer at a venture capital firm. Subsequent to December 9, Hans P. Hull who has been serving as interim CEO of Avalanche since July, will return to his previous role of senior vice president of business operations.

Read More

Read All Avalanche News